Phathom Pharmaceuticals, Inc. (PHAT) Tops Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PHAT Hot Sheet
Join SI Premium – FREE
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q4 EPS of ($0.80), $0.27 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $680 thousand versus the consensus estimate of $708.61 thousand.
For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Phathom Pharmaceuticals to Participate in November Investor Conferences
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
